Tradestie Institutional Equity Comparison Engine

CLYM vs MAIA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while MAIA counters with relative strength in Valuation. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MAIA at 1.2x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MAIA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner MAIA
CLYM N/M vs MAIA 1.2x Fwd P/E
Growth & Margin Winner CLYM
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner CLYM
1Y +399.5% vs +20.6% ยท 52W Pos 45% vs 10%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.19
-0.97% 1D
Market Cap $545.1M
1M Return -12.81%
1Y Return +399.46%
Forward P/E N/M
Unified AI Score
43.7 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 50.0 Mom 54.0
MAIA NYSE American
MAIA Biotechnology, Inc.
Pharmaceutical Preparations
$1.11
-2.63% 1D
Market Cap $68.5M
1M Return -1.77%
1Y Return +20.65%
Forward P/E 1.2x
Unified AI Score
37.6 / 100 SELL
Tech 40.0 Fund 38.0 Flow 50.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLYM +399.46% MAIA +20.65% Spread: +378.81 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLYM TTM Op. Margin: 0.0% MAIA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs MAIA. Trailing 12-month operating profitability (CLYM 0.0% vs MAIA 0.0%) and valuation multiples (CLYM N/M vs MAIA 1.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLYM (5) vs MAIA (2)
Institutional Metric CLYM MAIA Criterion Row Winner
Market Capitalization Scale $545.1M $68.5M Larger Scale CLYM
Trailing P/E Ratio Valuation N/M 1.2x Lower Multiple MAIA
Forward P/E Ratio Valuation N/M 1.2x Lower Multiple MAIA
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -29.3% -341.5% Higher ROE CLYM
52-Week Range Position Momentum 45% ($2โ€“$18) 10% ($1โ€“$3) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 106% Vol 1.65ฮฒ ยท 108% Vol Lower Realized Risk CLYM
Unified Institutional Score Composite Signal 43.7 / 100 (HOLD) 37.6 / 100 (SELL) Higher Composite CLYM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLYM vs MAIA Buy Guide
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MAIA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MAIA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLYM nor MAIA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.